Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for PainReform Ltd. (PRFX : NSDQ)

• Company Description    PainReform Ltd.is a clinical stage specialty pharmaceutical company. It engages in the development of products for the treatment of pain. The company's product pipeline includes PRF-110, a product based on local anesthetic ropivacaine, which is in clinical stage. PainReform Ltd.is based in Herzeliya, Israel. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $1.40 Daily Weekly Monthly 20 Day Moving Average: 316,456 shares Shares Outstanding: 2.01 (millions) Market Capitalization: $2.82 (millions) Beta: 0.56 52 Week High: $14.38 52 Week Low: $1.25 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.93% -31.59% 12 Week -31.71% -42.56% Year To Date -58.27% -60.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 65 YIGAL ALON ST. - TEL AVIV,L3 6744316 ISR ph: 972-3717-7051 fax: - prfx@crescendo-ir.com http://www.painreform.com

• General Corporate Information    Officers Ehud Geller - Chief Executive Officer and Executive Chairman Sigal Aviel - Chief Operating Officer Eyal Broder - Chief Financial Officer Rita Keynan - Vice President Efi Cohen-Arazi - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: M77798144 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/24 Next Expected EPS Date: 08/21/25 Share - Related Items Shares Outstanding: 2.01 Most Recent Split Date: 11.00 (0.25:1) Beta: 0.56 Market Capitalization: $2.82 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/21/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.67 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 85.29% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 1.81 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 1.81 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - 2.08 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©